Annual Debt To Equity
0.00
0.000.00%
31 December 2023
Summary:
Adaptimmune Therapeutics annual debt to equity ratio is currently 0.00, unchanged on 31 December 2023. During the last 3 years, it has risen by 0.00 (0.00%).ADAP Debt To Equity Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Debt To Equity
0.62
+0.36+138.46%
30 September 2024
Summary:
Adaptimmune Therapeutics quarterly debt to equity ratio is currently 0.62, with the most recent change of +0.36 (+138.46%) on 30 September 2024. Over the past year, it has increased by +0.62 (+100.00%). ADAP quarterly debt to equity is now at all-time high.ADAP Quarterly Debt To Equity Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ADAP Debt To Equity Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | 0.0% | +100.0% |
| 3 y3 years | 0.0% | +100.0% |
| 5 y5 years | 0.0% | +100.0% |
ADAP Debt To Equity High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | at high | |||
| 5 y | 5 years | at high | |||
| alltime | all time | at high | +100.0% | at high |
Adaptimmune Therapeutics Debt To Equity History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | 0.62(+138.5%) |
| June 2024 | - | 0.26(>+9900.0%) |
| Mar 2024 | - | 0.00(0.0%) |
| Dec 2023 | 0.00(0.0%) | 0.00(0.0%) |
| Sept 2023 | - | 0.00(0.0%) |
| June 2023 | - | 0.00(0.0%) |
| Mar 2023 | - | 0.00(0.0%) |
| Dec 2022 | 0.00(0.0%) | 0.00(0.0%) |
| Sept 2022 | - | 0.00(0.0%) |
| June 2022 | - | 0.00(0.0%) |
| Mar 2022 | - | 0.00(0.0%) |
| Dec 2021 | 0.00(0.0%) | 0.00(0.0%) |
| Sept 2021 | - | 0.00(0.0%) |
| June 2021 | - | 0.00(0.0%) |
| Mar 2021 | - | 0.00(0.0%) |
| Dec 2020 | 0.00(0.0%) | 0.00(0.0%) |
| Sept 2020 | - | 0.00(0.0%) |
| June 2020 | - | 0.00(0.0%) |
| Mar 2020 | - | 0.00(0.0%) |
| Dec 2019 | 0.00 | 0.00(0.0%) |
| Sept 2019 | - | 0.00(0.0%) |
| Date | Annual | Quarterly |
|---|---|---|
| June 2019 | - | 0.00(0.0%) |
| Mar 2019 | - | 0.00(0.0%) |
| Dec 2018 | 0.00(0.0%) | 0.00(0.0%) |
| Sept 2018 | - | 0.00(0.0%) |
| June 2018 | - | 0.00(0.0%) |
| Mar 2018 | - | 0.00(0.0%) |
| Dec 2017 | 0.00(0.0%) | 0.00(0.0%) |
| Sept 2017 | - | 0.00(0.0%) |
| June 2017 | - | 0.00(0.0%) |
| Mar 2017 | - | 0.00(0.0%) |
| Dec 2016 | 0.00(0.0%) | 0.00(0.0%) |
| Sept 2016 | - | 0.00(0.0%) |
| June 2016 | - | 0.00(0.0%) |
| Mar 2016 | - | 0.00(0.0%) |
| Dec 2015 | 0.00(0.0%) | - |
| Sept 2015 | - | 0.00(0.0%) |
| June 2015 | 0.00(0.0%) | - |
| Dec 2014 | - | 0.00(0.0%) |
| June 2014 | 0.00(-100.0%) | 0.00 |
| June 2013 | -0.71(<-9900.0%) | - |
| June 2012 | 0.00 | - |
FAQ
- What is Adaptimmune Therapeutics annual debt to equity ratio?
- What is the all time high annual debt to equity for Adaptimmune Therapeutics?
- What is Adaptimmune Therapeutics annual debt to equity year-on-year change?
- What is Adaptimmune Therapeutics quarterly debt to equity ratio?
- What is the all time high quarterly debt to equity for Adaptimmune Therapeutics?
- What is Adaptimmune Therapeutics quarterly debt to equity year-on-year change?
What is Adaptimmune Therapeutics annual debt to equity ratio?
The current annual debt to equity of ADAP is 0.00
What is the all time high annual debt to equity for Adaptimmune Therapeutics?
Adaptimmune Therapeutics all-time high annual debt to equity ratio is 0.00
What is Adaptimmune Therapeutics annual debt to equity year-on-year change?
Over the past year, ADAP annual debt to equity ratio has changed by 0.00 (0.00%)
What is Adaptimmune Therapeutics quarterly debt to equity ratio?
The current quarterly debt to equity of ADAP is 0.62
What is the all time high quarterly debt to equity for Adaptimmune Therapeutics?
Adaptimmune Therapeutics all-time high quarterly debt to equity ratio is 0.62
What is Adaptimmune Therapeutics quarterly debt to equity year-on-year change?
Over the past year, ADAP quarterly debt to equity ratio has changed by +0.62 (+100.00%)